These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28133895)

  • 1. Robust inference for group sequential trials.
    Ganju J; Lin Y; Zhou K
    Pharm Stat; 2017 Mar; 16(2):167-173. PubMed ID: 28133895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust inference from multiple test statistics via permutations: a better alternative to the single test statistic approach for randomized trials.
    Ganju J; Yu X; Ma GJ
    Pharm Stat; 2013; 12(5):282-90. PubMed ID: 23922313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential for increased power from combining P-values testing the same hypothesis.
    Ganju J; Julie Ma G
    Stat Methods Med Res; 2017 Feb; 26(1):64-74. PubMed ID: 24919832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new futility test approach in clinical interim data monitoring.
    Xue D
    Pharm Stat; 2012; 11(6):468-75. PubMed ID: 23015479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An optimised multi-arm multi-stage clinical trial design for unknown variance.
    Grayling MJ; Wason JMS; Mander AP
    Contemp Clin Trials; 2018 Apr; 67():116-120. PubMed ID: 29474933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses.
    Chen LM; Ibrahim JG; Chu H
    J Biopharm Stat; 2014; 24(4):817-33. PubMed ID: 24697500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice of futility boundaries for group sequential designs with two endpoints.
    Schüler S; Kieser M; Rauch G
    BMC Med Res Methodol; 2017 Aug; 17(1):119. PubMed ID: 28789615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal timing for interim analyses in clinical trials.
    Togo K; Iwasaki M
    J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to deal with multiple endpoints in clinical trials.
    Neuhäuser M
    Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introducing a new estimator and test for the weighted all-cause hazard ratio.
    Ozga AK; Rauch G
    BMC Med Res Methodol; 2019 Jun; 19(1):118. PubMed ID: 31185922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.
    Hamasaki T; Evans SR; Asakura K
    J Biopharm Stat; 2018; 28(1):28-51. PubMed ID: 29083951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-stage group sequential robust tests in family-based association studies: controlling type I error.
    Yan LK; Zheng G; Li Z
    Ann Hum Genet; 2008 Jul; 72(Pt 4):557-65. PubMed ID: 18325081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.
    Yi J; Fang L; Su Z
    Contemp Clin Trials; 2012 Jan; 33(1):138-42. PubMed ID: 21983624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
    Potthoff RF; Halabi S
    Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.